+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Osteomyelitis (Infectious Disease) - Drugs In Development, 2021

  • ID: 5359605
  • Drug Pipelines
  • June 2021
  • Region: Global
  • 55 pages
  • Global Markets Direct

FEATURED COMPANIES

  • BioVinc LLC
  • ContraFect Corp
  • Nabriva Therapeutics Plc
  • Sonoran Biosciences Inc
  • Telephus Medical LLC
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Osteomyelitis (Infectious Disease) - Drugs In Development, 2021, provides an overview of the Osteomyelitis (Infectious Disease) pipeline landscape.

Osteomyelitis is an infection in a bone. Infections can reach a bone by traveling through the bloodstream or spreading from nearby tissue. Symptoms include fever, pain in the area of the infection, swelling, warmth and redness over the area of the infection and irritability. Risk factors bone fracture, sickle cell disease, chemotherapy, diabetes and peripheral arterial disease. Treatment includes surgery and oral antibiotics.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Osteomyelitis (Infectious Disease) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Osteomyelitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteomyelitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Osteomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, IND/CTA Filed and Preclinical stages are 1, 1 and 6 respectively.

Osteomyelitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteomyelitis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Osteomyelitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteomyelitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteomyelitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteomyelitis (Infectious Disease)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteomyelitis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteomyelitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • BioVinc LLC
  • ContraFect Corp
  • Nabriva Therapeutics Plc
  • Sonoran Biosciences Inc
  • Telephus Medical LLC
  • MORE
Introduction
  • Report Coverage
Osteomyelitis - Overview

Osteomyelitis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
Osteomyelitis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Osteomyelitis - Companies Involved in Therapeutics Development
  • Adaptive Phage Therapeutics Inc
  • BioVinc LLC
  • ContraFect Corp
  • Debiopharm International SA
  • Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd
  • Nabriva Therapeutics Plc
  • Sonoran Biosciences Inc
  • Telephus Medical LLC
Osteomyelitis - Drug Profiles

(tobramycin + vancomycin SR) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
afabicin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Biologics for Coronavirus Disease 2019 (COVID-19), Urinary Tract, Prosthetic Joint and Bacterial Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
BV-600022 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
ceforanide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
CF-296 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
lefamulin acetate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
TPH-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Osteomyelitis - Dormant Projects

Osteomyelitis - Product Development Milestones

Featured News & Press Releases
  • Mar 10, 2021: Adaptive Phage Therapeutics announces FDA clearance of IND application for PhageBank in treatment of diabetic foot osteomyelitis
  • Dec 11, 2017: Telephus Biosciences Appoints Patrick Vink, M.D., MBA, William Boyle, Ph.D., and Richard Proctor, M.D., as Company Advisors
  • Apr 08, 2016: Debiopharm International to present the latest findings on Debio 1450 at ECCMID
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Number of Products under Development for Osteomyelitis, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Osteomyelitis - Pipeline by Adaptive Phage Therapeutics Inc, 2021
  • Osteomyelitis - Pipeline by BioVinc LLC, 2021
  • Osteomyelitis - Pipeline by ContraFect Corp, 2021
  • Osteomyelitis - Pipeline by Debiopharm International SA, 2021
  • Osteomyelitis - Pipeline by Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd, 2021
  • Osteomyelitis - Pipeline by Nabriva Therapeutics Plc, 2021
  • Osteomyelitis - Pipeline by Sonoran Biosciences Inc, 2021
  • Osteomyelitis - Pipeline by Telephus Medical LLC, 2021
  • Osteomyelitis - Dormant Projects, 2021
List of Figures
  • Number of Products under Development for Osteomyelitis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
Note: Product cover images may vary from those shown
  • Adaptive Phage Therapeutics Inc
  • BioVinc LLC
  • ContraFect Corp
  • Debiopharm International SA
  • Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd
  • Nabriva Therapeutics Plc
  • Sonoran Biosciences Inc
  • Telephus Medical LLC
Note: Product cover images may vary from those shown
Adroll
adroll